
The umbrella term psoriasis is now understood to incorporate several distinct phenotypes or endotypes along the disease spectrum that in turn will dictate different therapies. A stratified medicine approach to psoriasis using this clinical information coupled with pharmacogenomic and immunologic data will become more widely acceptable in the future. Comorbidities associated with psoriasis, such as diabetes, depression, and Crohn disease, and the debate about the interdependence of psoriasis and cardiovascular disease will also dictate future research and holistic and management plans for this complex disease.
Biosimilars, Clinical Trials as Topic, Tumor Necrosis Factor-alpha, Interleukin-17, Systemic disease, Antibodies, Monoclonal, Personalized medicine, Phenotype, Psoriatic arthritis, Humans, Psoriasis, Dermatologic Agents, Precision Medicine, Drug safety, Biosimilar Pharmaceuticals, Phenotypical variants, Forecasting
Biosimilars, Clinical Trials as Topic, Tumor Necrosis Factor-alpha, Interleukin-17, Systemic disease, Antibodies, Monoclonal, Personalized medicine, Phenotype, Psoriatic arthritis, Humans, Psoriasis, Dermatologic Agents, Precision Medicine, Drug safety, Biosimilar Pharmaceuticals, Phenotypical variants, Forecasting
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 20 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
